# Rapamycin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rapamycin

> The PDUFA target action date for rapamycin, sponsored by PALVELLA THERAPEUTICS, INC. (PVLA), is February 28, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the rapamycin PDUFA date?

The PDUFA target action date for rapamycin, sponsored by PALVELLA THERAPEUTICS, INC. (PVLA), is February 28, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "FDA Accepts NDA for QTORIN Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027" Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/rapamycin)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-448594, https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/rapamycin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | rapamycin |
| Codes | PTX-022 |
| Sponsor | PALVELLA THERAPEUTICS, INC. (PVLA) https://sec-api.dev/companies/pvla/catalysts |
| Indications | cutaneous vms, [cutaneous venous malformations](https://sec-api.dev/indications/cutaneous-venous-malformations), [microcystic lm](https://sec-api.dev/indications/microcystic-lm), microcystic lms in patients 3 years and older, microcystic lymphatic malformations |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### Q4 2024: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2024-12-31, last confirmed 2024-12-31.
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We plan to initiate our Phase 2 clinical trial, a 12-week, multicenter, baseline-controlled Phase 2 clinical trial of QTORIN rapamycin in up to 20 patients with cutaneous venous malformations in the 4th quarter of 2024." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm

### Nov 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-31, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047206): "In November 2024, Palvella dosed the first patient in the Phase 3 SELVA study." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm

### May 14, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-03-26, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034951): "On May 14, 2025, the Company announced positive initial data from its investigator led Peeling Skin Syndrome (PSS) clinical study which is being conducted in a single patient in New Zealand." https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_ex99-1.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: cutaneous venous malformations.
- First seen 2024-12-16, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108422): "Top-line results for Phase 2 TOIVA trial evaluating QTORIN rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071988): "Phase 2 TOIVA trial evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047206): "Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations (cutaneous VMs), on track for the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-047212): "We are also conducting a Phase 2 clinical trial of QTORIN rapamycin for the treatment of cutaneous VMs, for which we expect to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We are also planning to conduct a Phase 2 clinical trial of QTORIN rapamycin for the treatment of cutaneous venous malformations, for which it expects to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-037515): "Palvella is conducting a Phase 2 baseline-controlled clinical trial in approximately 15 participants in this patient population and expects to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000143774924037515/ex_755593.htm
- SEC Form 10-K (accession 0000950170-25-047212): "In the first quarter of 2025, we announced the first patients have been dosed in our Phase 2 TOIVA trial in patients with cutaneous VMs and expect to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "This Phase 2 baseline-controlled clinical trial is expected to be in approximately 15 participants in this patient population and we expect to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We are conducting a Phase 2 baseline-controlled clinical trial in approximately 15 participants in this patient population and expect to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We plan to initiate our Phase 2 trial in patients with cutaneous venous malformations in the fourth quarter of 2024 and expect to report top-line data in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm

### December 15, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-31, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-120789): "2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)" https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_ex99-2.htm
- SEC Form 10-Q (accession 0001193125-26-448638): "In December 2025, we announced positive topline efficacy results from TOIVA, a multicenter, single-arm, open-label, baseline-controlled, Phase 2 clinical trial designed to evaluate the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-331574): "In December 2025, we announced positive topline efficacy results from TOIVA, a multicenter, single-arm, open-label, baseline-controlled, Phase 2 clinical trial designed to evaluate the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331574/pvla-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-210463): "In December 2025, we announced positive topline efficacy results from TOIVA, a multicenter, single-arm, open-label, baseline-controlled, Phase 2 clinical trial designed to evaluate the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526210463/pvla-20260331.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In December 2025, we announced positive topline efficacy results from TOIVA, a Phase 2, single-arm, baseline-controlled study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs in patients 6 years and older, which achieved nominal statistical significance (p<0.001) on multiple pre-specified clinician-reported and patient-reported efficacy endpoints, including dynamic change endpoints and static severity endpoints at Week 12." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In December 2025, we announced positive topline results from TOIVA, a multicenter, single-arm, open-label, baseline-controlled, Phase 2 clinical trial designed to evaluate the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In December 2025, we announced positive topline efficacy results from TOIVA, a multicenter, single-arm, open-label, baseline-controlled, Phase 2 clinical trial designed to evaluate the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In December 2025, we announced positive topline efficacy results from the Phase 2 TOIVA study, a 12-week, multicenter, single-arm, open-label, baseline-controlled Phase 2 clinical trial of QTORIN rapamycin for cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC prospectus (424B) (accession 0001104659-26-020659): "In December 2025, we announced positive topline efficacy results from the Phase 2 TOIVA study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs in patients 6 years and older, which achieved statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy endpoints, including dynamic change endpoints and static severity endpoints." https://www.sec.gov/Archives/edgar/data/1583648/000110465926020659/tm2534019-7_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-020659): "In December 2025, we announced positive topline results from our Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000110465926020659/tm2534019-7_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-019152): "In December 2025, we announced positive topline efficacy results from the Phase 2 TOIVA study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs in patients 3 years and older, which achieved statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy endpoints, including dynamic change endpoints and static severity endpoints." https://www.sec.gov/Archives/edgar/data/1583648/000110465926019152/tm2534019-4_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-019152): "In December 2025, we announced positive topline results from our Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin for the treatment of cutaneous VMs." https://www.sec.gov/Archives/edgar/data/1583648/000110465926019152/tm2534019-4_424b5.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: microcystic LM.
- First seen 2024-12-16, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108422): "Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047206): "Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-047212): "We are currently conducting our Phase 3 clinical trial of QTORIN rapamycin for the treatment of microcystic LM, for which we expect to report top-line data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- SEC Form 10-K (accession 0000950170-25-047212): "We are currently conducting a Phase 3 clinical trial of QTORIN rapamycin for the treatment of microcystic LM, for which we expect to report top-line data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We are currently conducting our Phase 3 clinical trial of QTORIN rapamycin for the treatment of microcystic LM, for which it expects to report top-line data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We expect to report top-line data from our Phase 3 trial of QTORIN rapamycin for the treatment of microcystic LM in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We are currently conducting a Phase 3 clinical trial of QTORIN rapamycin for the treatment of microcystic LM, for which it expects to report top-line data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-274378): "This will be followed by a Phase 3 topline readout in microcystic lymphatic malformations which we anticipate in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071988): "Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-037515): "Palvella expects to report top-line data for the Phase 3 study in approximately 40 participants with microcystic LM in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000143774924037515/ex_755593.htm
- SEC Form 10-K (accession 0000950170-25-047212): "We expect to report top-line data from our Phase 3 SELVA trial in microcystic LM in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- SEC registration statement (S-1) (accession 0001437749-24-038553): "We expect to report top-line data for the Phase 3 study in approximately 40 participants with microcystic LM in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm

### February 24, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-31, last confirmed 2026-05-20.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065159): "WAYNE, Pa., February 24, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat participants suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs)." https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-210463): "In February 2026, we announced positive topline results from SELVA, a Phase 3, single-arm, baseline-controlled study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older." https://www.sec.gov/Archives/edgar/data/1583648/000119312526210463/pvla-20260331.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In February 2026, we announced positive topline results from SELVA, a Phase 3, single-arm, baseline-controlled study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In February 2026, we announced positive topline results from SELVA, the Phase 3, single-arm, baseline-controlled study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In February 2026, we announced positive topline results from SELVA, a Phase 3, single-arm, baseline-controlled clinical trial evaluating once-daily QTORIN rapamycin in individuals aged ≥ 3 years with microcystic LMs." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-133332): "In February 2026, reported positive topline results from the Phase 3 SELVA study:" https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047206): "Top-line results from TOIVA are anticipated in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108422): "Top-line results from TOIVA are on track for the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071988): "Top-line results from TOIVA are anticipated in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-276119): "We expect to report top-line data for the TOIVA study in mid-December 2025." https://www.sec.gov/Archives/edgar/data/1583648/000119312525276119/pvla-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-108438): "We expect to report top-line data for the TOIVA study in approximately 15 participants with cutaneous VMs in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025108438/pvla-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071998): "We expect to report top-line data for the TOIVA study in approximately 15 participants with cutaneous VMs in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1583648/000095017025071998/pvla-20250331.htm

### Mar 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-03-31, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001193125-26-210463): "In March 2026, we submitted a pre-NDA meeting request to" https://www.sec.gov/Archives/edgar/data/1583648/000119312526210463/pvla-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-133332): "In March 2026, submitted Pre-NDA meeting request to FDA, with meeting anticipated in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: clinically significant angiokeratomas planned for second quarter of 2026.
- First seen 2026-03-31, last confirmed 2026-05-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-133332): "Initiation of Phase 2 trial of QTORIN rapamycin for the treatment of clinically significant angiokeratomas planned for second quarter of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-133372): "QTORIN rapamycin is in clinical development for microcystic LMs and cutaneous VMs, and we plan to initiate a Phase 2 clinical study in clinically significant angiokeratomas in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000030): "•Initiation of the Phase 2 trial of Qtorin rapamycin for the treatment of clinically significant angiokeratomas is planned for second quarter of 2026" https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/q12026earningsrelease_ex991.htm
- SEC Form 10-Q (accession 0000886163-26-000034): "•Initiation of the Phase 2 trial of Qtorin rapamycin for the treatment of clinically significant angiokeratomas is planned for second quarter of 2026" https://www.sec.gov/Archives/edgar/data/886163/000088616326000034/lgnd-20260331.htm

### April 13, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000003): "The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026." https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm

### April 29, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000003): "The target action date for the FDA decision is April 29, 2026." https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm

### Jun 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-08-04, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448638): "In June 2026, we submitted the first module of our rolling NDA, and in August 2026, we completed the rolling submission." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-331574): "In June 2026, we submitted the first module of our rolling NDA." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331574/pvla-20260630.htm

### 2H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3. Indication: microcystic LM.
- First seen 2025-03-31, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-232717): "Palvella plans to submit a New Drug Application to the U.S. FDA for QTORIN rapamycin for Microcystic LMs in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210605): "FDA Pre-New Drug Application (NDA) meeting granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065159): "Based on these results, Palvella plans to submit a New Drug Application (NDA) to FDA for QTORIN rapamycin for patients with microcystic LMs in the second half of 2026, with potential U.S. approval for QTORIN rapamycin in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065159): "These data support the potential for QTORIN rapamycin to become the first FDA-approved therapy for microcystic LMs as we advance toward submission of a planned NDA in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108422): ""We remain on track for two near-term data readouts for QTORIN rapamycin, including our Phase 3 SELVA study in microcystic LMs which we believe will support a New Drug Application submission in 2026." https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-133372): "In the first quarter of 2026, we reported topline data from our Phase 3 clinical trial of QTORIN rapamycin for the treatment of microcystic LM, and are planning for a potential NDA submission to the FDA in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "We completed our Phase 3 clinical trial evaluating QTORIN rapamycin in patients with microcystic LM and are planning for a potential NDA submission in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0001193125-26-133372): "We reported topline data from our Phase 3 trial of QTORIN rapamycin for the treatment of microcystic LM in the first quarter of 2026 and are planning for a potential NDA submission in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- SEC Form 10-K (accession 0000950170-25-047212): "Assuming favorable results from SELVA, we plan to request FDA agreement to begin a rolling submission of a Section 505(b)(2) New Drug Application ("NDA") for QTORIN rapamycin for the treatment of microcystic LM in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "Completion of the NDA submission remains on track for the second half of 2026, and we are preparing for a planned standalone commercial launch in the first half of 2027, if approved." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "The Company remains on track to complete the NDA submission in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-232717): "We remain on track to file our NDA in the second half of 2026 for microcystic lymphatic malformations, with potential approval targeted in the first half of 2027."" https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-ex99_1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Indication: Netherton Syndrome.
- First seen 2026-03-26, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034951): "NDA approval in 2027, reporting topline data from two whole-body clinical trials for the treatment of Netherton Syndrome in the second half of 2026, initiating proof of concept clinical testing in the second half of 2026 in at least one clinical indication for Quoin's rapamycin topical lotion and dermal patch platforms, the Company's year-end cash position funding operations into 2027, and Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton" https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_ex99-1.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: cutaneous venous malformations planned for second half of 2026.
- First seen 2026-03-31, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "Initiation of Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-232717): "Palvella plans to initiate a Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210605): "Initiation of Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-133332): "Initiation of Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-133372): "We intend to commence a Phase 3 pivotal trial evaluating QTORIN rapamycin in patients with cutaneous VMs in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000030): "•Initiation of the Phase 3 trial of Qtorin rapamycin for the treatment of cutaneous venous malformations is planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/q12026earningsrelease_ex991.htm
- SEC Form 10-Q (accession 0000886163-26-000034): "•Initiation of the Phase 3 trial of Qtorin rapamycin for the treatment of cutaneous venous malformations is planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/886163/000088616326000034/lgnd-20260331.htm

### October 28, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: microcystic lymphatic malformations.
- First seen 2026-10-28, last confirmed 2026-10-28.
- SEC Form 8-K (accession 0001193125-26-435113): "On October 28, 2026, Palvella Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted for filing and granted Priority Review to the Company's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations." https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-20261028.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-435113): "WAYNE, Pa., October 28, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Nasdaq: PVLA) ("Palvella" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the FDA has accepted for filing and granted Priority Review to the Company's New Drug Application (NDA) for QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs)." https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-ex99_1.htm

### February 28, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2026-10-28, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-448594): "FDA Accepts NDA for QTORIN Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027" https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-448594): "Completed the NDA submission for QTORIN rapamycin, which was accepted by the FDA with a February 28, 2027 PDUFA target action date." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-435113): "Palvella Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set" https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-435113): "The FDA has assigned a Prescription Drug User Fee Act target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-20261028.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-435113): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-435113): "With compelling Phase 3 SELVA results and a February 28, 2027 PDUFA target action date, we believe we are closer than ever to delivering on that mission." https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-448638): "The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-448638): "The FDA assigned a PDUFA target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000058): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/q32026earningsrelease_ex991.htm
- SEC Form 10-Q (accession 0000886163-26-000060): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000060/lgnd-20260930.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-05-07, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-448594): "Topline results from LOTU are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "Topline results from LOTU are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210605): "Topline results from LOTU are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-448638): "Topline results are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-331574): "Topline results are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526331574/pvla-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-210463): "Topline results are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1583648/000119312526210463/pvla-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "Topline results from the Phase 2 LOTU trial of QTORIN rapamycin for clinically significant angiokeratomas expected in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210605): "Phase 2 LOTU trial of QTORIN rapamycin for clinically significant angiokeratomas initiated with topline results expected in second half of 2027" https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000041): "Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. Topline results from the Phase 2 trial are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/q22026earningsrelease_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000030): "Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. Topline results from the Phase 2 trial are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/q12026earningsrelease_ex991.htm
- SEC Form 10-Q (accession 0000886163-26-000044): "Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. Topline results from the Phase 2 trial are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000044/lgnd-20260630.htm
- SEC Form 10-Q (accession 0000886163-26-000034): "Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA approved therapies and estimated more than 50,000 diagnosed patients in the U.S. Topline resulting from the Phase 2 trial are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/886163/000088616326000034/lgnd-20260331.htm

Calendar months: [April 2026](https://sec-api.dev/fda-calendar/2026-04), [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rapamycin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rapamycin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rapamycin

```bibtex
@misc{secapidev_pdufa_rapamycin_20261116,
  title        = {Rapamycin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rapamycin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rapamycin_20261116","title":"Rapamycin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rapamycin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
